Skip to main content

ProMetic to Develop Synthetic Affinity Ligand for Novartis' Vaccine Program

NEW YORK (GenomeWeb News) — Synthetic protein drug developer ProMetic Biosciences will develop a synthetic ligand affinity for Novartis, the company said today.
 
PBL, a subsidiary of ProMetic Life Sciences, said Novartis Vaccines has hired it to screen chemical libraries for ligands that may be used to purify a new vaccine product Novartis currently has in clinical trials.
 
PBL, based in Montreal, said it will conduct the screenings using its Mimetic protein replacement system at its labs at the Cambridge Science Park, in Cambridge, UK.
 
Financial terms of the agreement were not released.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.